Ethical Considerations in Decentralized Clinical Trials.
Bioethics
Decentralized clinical trials
Digital trials
Electronic Consent
Hybrid trials
Remote trials
Journal
Journal of bioethical inquiry
ISSN: 1872-4353
Titre abrégé: J Bioeth Inq
Pays: Netherlands
ID NLM: 101250741
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
30
08
2023
accepted:
29
01
2024
medline:
18
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
ppublish
Résumé
As a consequence of the COVID-19 pandemic, the number of decentralized clinical trials, trials conducted in whole or in part at locations other than traditional clinical trial sites, significantly increased. While these trials have the potential advantage of access, participant centricity, convenience, lower costs, and efficiency, they also raise a number of important ethical and practical concerns. Here we focus on a number of those concerns, including participant safety, privacy and confidentiality, remote consent, digital access and proficiency, and trial oversight. Awareness of these ethical complexities will help foster the development of processes and cooperative solutions to promote safe, ethical trials going forward, optimized to decrease burden and increase access for all participants.
Identifiants
pubmed: 38427177
doi: 10.1007/s11673-024-10341-3
pii: 10.1007/s11673-024-10341-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
711-718Informations de copyright
© 2024. Journal of Bioethical Inquiry Pty Ltd.
Références
Adams D.V., S. Long, and M.E. Fleury. 2022. Association of remote technology use and other decentralization tools with patient likelihood to enroll in cancer clinical trials. JAMA Network Open 5(7): e2220053.
doi: 10.1001/jamanetworkopen.2022.20053
pubmed: 35788672
pmcid: 9257574
AlSaleh, K.A. 2021. Clinical Trials before, during, and after COVID-19 Pandemic. American Journal of Clinical Oncology 44(2): 90–91.
doi: 10.1097/COC.0000000000000783
pubmed: 33475281
Borno H.T., L. Zhang, A. Siegel, E. Chang, and C.J. Ryan. 2018. At what cost to clinical trial enrollment? A retrospective study of patient travel burden in cancer clinical trials. Oncologist 23(10): 1242–1249.
doi: 10.1634/theoncologist.2017-0628
pubmed: 29700209
pmcid: 6263122
Desai, M. 2020. Recruitment and retention of participants in clinical studies: Critical issues and challenges. Perspectives in Clinical Research 11(2): 51–53.
doi: 10.4103/picr.PICR_6_20
pubmed: 32670827
pmcid: 7342339
Doroshow J.H., S. Prindiville, W. McCaskill-Stevens, M. Mooney, and P.J. Loehrer. 2021. COVID-19, social justice, and clinical cancer research. JNCI: Journal of the National Cancer Institute 113(10): 1281–1284.
European Commission. 2022. Guidance on the management of clinical trials during the COVID-19 (coronavirus) pandemic. https://health.ec.europa.eu/system/files/2022-02/guidanceclinicaltrials_covid19_en_1.pdf . Accessed August 13, 2023.
Federal Trade Commission. 2015. Broadband Progress Report. February 4. https://www.fcc.gov/reports-research/reports/broadband-progress-reports/2015-broadband-progress-report/ . Accessed August 19, 2023.
Flaherty K.T., J.H. Doroshow, S. Galbraith, et al. 2021. Rethinking cancer clinical trial conduct induced by COVID-19: An academic center, industry, government, and regulatory agency perspective. Cancer Discovery 11(8): 1881–1885.
doi: 10.1158/2159-8290.CD-21-0850
pubmed: 34290074
pmcid: 8340848
Hauck C.L., T.J. Kelechi, K.B. Cartmell, and M. Mueller. 2021. Trial-level factors affecting accrual and completion of oncology clinical trials: A systematic review. Contemporary Clinical Trials Communications 24: 100843.
doi: 10.1016/j.conctc.2021.100843
pubmed: 34765799
pmcid: 8573122
Ledford H. 2020. Coronavirus shuts down trials of drugs for multiple other diseases. Nature 580(7801): 15–17.
doi: 10.1038/d41586-020-00889-6
pubmed: 32214240
Loucks T.L., C. Tyson, D. Dorr, et al. 2021. Clinical research during the COVID-19 pandemic: The role of virtual visits and digital approaches. Journal of Clinical and Translational Science 5(1): e102.
doi: 10.1017/cts.2021.19
pubmed: 34192057
pmcid: 8185429
Malone M., P. Ferguson, A. Rogers, et al. 2022. When innovation outpaces regulations: The legal challenges for direct‐to‐patient supply of investigational medicinal products. British Journal of Clinical Pharmacology 88(3): 1115–1142.
doi: 10.1111/bcp.15040
pubmed: 34390022
Nicholson, L.M., P.M. Schwirian, E.G. Klein, et al. 2011. Recruitment and retention strategies in longitudinal clinical studies with low-income populations. Contemporary Clinical Trials 32(3): 353–362.
doi: 10.1016/j.cct.2011.01.007
pubmed: 21276876
pmcid: 3070062
Nipp R.D., E. Powell, B. Chabner, and B. Moy. 2015. Recognizing the financial burden of cancer patients in clinical trials. Oncologist 20(6): 572–575.
doi: 10.1634/theoncologist.2015-0068
pubmed: 25986245
pmcid: 4571792
Noor, N.M., A.L. Hart, P.M. Irving, et al. 2020. Clinical trials [and tribulations]: The immediate effects of COVID-19 on IBD clinical research activity in the U.K. Journal of Crohn’s and Colitis 14(12): 1769–1776.
Signé, L. 2023. Fixing the global digital divide and digital access gap. July 5. Brookings Institute. https://www.brookings.edu/articles/fixing-the-global-digital-divide-and-digital-access-gap/ . Accessed August 19, 2023.
The Commonwealth Department of Health. 2020. National principles for clinical trials, including teletrials in Australia. https://www.health.gov.au/sites/default/files/documents/2021/03/national-principles-for-teletrials-in-australia.pdf . Accessed August 13, 2023.
US Food and Drug Administration (FDA). 2016. Use of electronic informed consent questions and answers: Guidance for Institutional Review Boards, investigators, and sponsors. https://www.fda.gov/media/116850/download . Accessed August 26, 2023.
———. 2020a. FDA guidance on conduct of clinical trials of medical products during the COVID-19 public health emergency. Updated August 30, 2021. https://www.fda.gov/media/136238/download . Accessed August 13, 2023.
———. 2020b. Statistical considerations for clinical trials during the COVID-19 public health emergency—Guidance for industry. Updated August 30, 2021. https://www.fda.gov/media/136238/download . Accessed August 13, 2023.
———. 2023. Guidance for IRBs, clinical investigators, and sponsors. https://www.fda.gov/media/88915/download . Accessed August 19, 2023
Wendler D., R. Kington, J. Madans, et al. 2006. Are racial and ethnic minorities less willing to participate in health research? PLoS Medicine Feb 3(2): e19.
West D.M., and J. Karsten. 2016. Rural and urban America divided by broadband access. Brookings Institute. https://www.brookings.edu/articles/rural-and-urban-america-divided-by-broadband-access/ . Accessed August 19, 2023.